TABLE 1.
.Baseline characteristics according to diastolic function.
| No diastolic dysfunction No. = 176 (47%) | Diastolic dysfunction Grade 1 No. = 154 (41%) | Diastolic dysfunction Grade II+III No. = 43 (12%) | p | |
|---|---|---|---|---|
| Patient characteristics | ||||
| Male sex | 100 (56) | 118 (77) | 23 (53) | <.001 |
| Age (years) | 51 ± 14 | 64 ± 12 | 66 ± 16 | <.001 |
| Height (cm) | 170 ± 11 | 172 ± 9 | 168 ± 12 | .171 |
| Weight (kg) | 76 ± 21 | 79 ± 17 | 76 ± 15 | .125 |
| BMI (kg/m2) | 26.0 ± 6.6 | 27.0 ± 5.5 | 26.8 ± 4.6 | .176 |
| Medical history | ||||
| Arterial hypertension | 80 (45) | 115 (75) | 31 (72) | <.001 |
| Coronary artery disease | 0 (0) | 117 (76) | 20 (47) | <.001 |
| Heart failure | 0 (0) | 42 (27) | 7 (16) | <.001 |
| Valvular heart disease | 34 (19) | 30 (19) | 19 (44) | <.001 |
| Psychiatric disease | 23 (13) | 16 (10) | 4 (9) | .654 |
| Type 1&2 diabetes | 17 (10) | 39 (25) | 10 (23) | <.001 |
| Endocrinologic disease | 14 (8) | 11 (5) | 6 (14) | .352 |
| OSAS | 5 (3) | 8 (5) | 1 (2) | .469 |
| Positive family history for HTN | 38 (22) | 20 (13) | 7 (16) | .118 |
| NT‐proBNP (pg/mL) | 68 ± 346 | 152 ± 890 | 421 ± 2756 | <.001 |
| Medication history | ||||
| Beta blockers | 42 (24) | 95 (62) | 30 (70) | <.001 |
| ACE inhibitors /ARBs | 48 (27) | 106 (69) | 29 (67) | <.001 |
| Calcium channel blocker | 29 (16) | 41 (27) | 18 (42) | .001 |
| Diuretics | 28 (16) | 58 (38) | 22 (51) | <.001 |
| Antiplatelet agents | 32 (18) | 123 (80) | 18 (42) | <.001 |
| Oral anticoagulants | 11 (6) | 19 (12) | 14 (33) | <.001 |
| Statins | 27 (15) | 111 (72) | 22 (51) | <.001 |
| Other cardiac medication | 13 (7) | 21 (14) | 8 (19) | .054 |
Data are shown as mean and standard deviation. Categorical data are shown as numbers and percentages. p values are based on Kruskal‐Wallis test or Chi‐square test as appropriate.
Abbreviations: ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; HTN, arterial hypertension; OSAS, obstructive sleep apnea syndrome.